Isomorphic Labs secures $5 billion Series C led by Sequoia and Greenoaks
Artificial intelligence drug discovery company Isomorphic Labs is raising fresh capital as competition intensifies in the biotech and AI sectors. The Alphabet-owned group has secured $5 billion just six months after disclosing its previous fundraising effort, marking a rapid pace of financing.
Highlights
- Isomorphic Labs secures $5 billion Series C financing led by Sequoia Capital and Greenoaks, with participation from Andreessen Horowitz, Thrive Capital, GV, and CapitalG.
- The funding round demonstrates sustained investor appetite for AI-driven pharmaceutical research and ongoing interest from major Silicon Valley and life sciences investors.
- The capital raise positions Isomorphic Labs with significant resources to accelerate AI-based drug discovery and signals robust private market support for biotech-technology convergence.
Funding round brings in major Silicon Valley backers
As first reported by Bloomberg, Sequoia Capital and Greenoaks are leading Isomorphic Labs' Series C funding round, which the company is set to announce Tuesday. Other new investors include Andreessen Horowitz, while existing backers Thrive Capital and Alphabet's venture arms GV and CapitalG are also participating in the latest raise.The new financing adds to a recent fundraising effort by the company and underscores continued investor appetite for businesses applying artificial intelligence to pharmaceutical research. Isomorphic Labs is focused on designing new drugs with AI, placing it within a fast-growing segment that is attracting both technology and life sciences capital.
AI drug development draws sustained capital
The $5 billion raise highlights how large investors are continuing to back companies that promise to shorten drug discovery timelines and improve research productivity through machine learning. For Alphabet, the round also reinforces its exposure to commercial applications of AI beyond its core internet and software businesses.The deal positions Isomorphic Labs with substantial financial resources as it expands work on AI-driven drug design. It also signals that private market funding remains available at scale for companies operating at the intersection of biotechnology and advanced computing.
The latest update follows our earlier article on Anthropic IPO pricing and New Street’s $105 target ahead of its expected debut.